Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Recommendation of “Hold” from Analysts

Moderna, Inc. (NASDAQ:MRNA) has been given a consensus recommendation of “Hold” by the twenty-two analysts that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $79.50.

Several research firms have recently issued reports on MRNA. JPMorgan Chase & Co. lowered their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research report on Tuesday, November 26th. Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Jefferies Financial Group lowered their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Barclays lowered their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Finally, Bank of America reaffirmed an “underperform” rating and set a $41.00 price objective on shares of Moderna in a research report on Tuesday, December 10th.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Moderna

A number of large investors have recently modified their holdings of MRNA. Larson Financial Group LLC raised its stake in shares of Moderna by 1,753.1% during the 2nd quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock worth $70,000 after buying an additional 561 shares in the last quarter. TD Asset Management Inc increased its stake in Moderna by 13.8% in the 2nd quarter. TD Asset Management Inc now owns 162,137 shares of the company’s stock valued at $19,254,000 after purchasing an additional 19,599 shares in the last quarter. Private Advisor Group LLC increased its stake in Moderna by 112.1% in the 2nd quarter. Private Advisor Group LLC now owns 30,733 shares of the company’s stock valued at $3,650,000 after purchasing an additional 16,243 shares in the last quarter. Lake Street Advisors Group LLC increased its stake in Moderna by 6.8% in the 2nd quarter. Lake Street Advisors Group LLC now owns 3,991 shares of the company’s stock valued at $474,000 after purchasing an additional 253 shares in the last quarter. Finally, Asset Dedication LLC increased its stake in Moderna by 41.8% in the 2nd quarter. Asset Dedication LLC now owns 1,018 shares of the company’s stock valued at $121,000 after purchasing an additional 300 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $42.57 on Tuesday. The stock’s 50-day moving average is $43.38 and its two-hundred day moving average is $71.48. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47. The company has a market cap of $16.38 billion, a price-to-earnings ratio of -7.31 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.39) EPS. Analysts forecast that Moderna will post -9.3 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.